| 2.53 0.02 (0.8%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.77  |
1-year : | 4.5 |
| Resists | First : | 3.23 |
Second : | 3.85 |
| Pivot price | 2.44 |
|||
| Supports | First : | 2.22 | Second : | 1.85 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 2.5 |
| MA(100) : | 3.56 |
MA(250) : | 4.03 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 42.6 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 7.73 | Low : | 2.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PBYI ] has closed below upper band by 29.8%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.63 - 2.64 | 2.64 - 2.65 |
| Low: | 2.47 - 2.48 | 2.48 - 2.49 |
| Close: | 2.51 - 2.53 | 2.53 - 2.54 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Sat, 07 Sep 2024
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment? - Simply Wall St
Tue, 03 Sep 2024
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Tue, 03 Sep 2024
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Wed, 14 Aug 2024
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - Seeking Alpha
Thu, 01 Aug 2024
Puma Biotechnology Reports Second Quarter Financial Results - StockTitan
Thu, 18 Jul 2024
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 15.1 (%) |
| Held by Institutions | 69.7 (%) |
| Shares Short | 3,480 (K) |
| Shares Short P.Month | 3,820 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 3.9 % |
| Operating Margin | -4.7 % |
| Return on Assets (ttm) | 6 % |
| Return on Equity (ttm) | 22.1 % |
| Qtrly Rev. Growth | -13.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.46 |
| EBITDA (p.s.) | 0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 33 (M) |
| Levered Free Cash Flow | 37 (M) |
| PE Ratio | 13.31 |
| PEG Ratio | 0 |
| Price to Book value | 2.52 |
| Price to Sales | 0.56 |
| Price to Cash Flow | 3.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|